Related Experiment Videos
Chronic intrathecal baclofen administration in severe spasticity
J Broseta1, G García-March, M J Sánchez-Ledesma
1Department of Neurosurgery, University of Salamanca, Spain.
Stereotactic and Functional Neurosurgery
|January 1, 1990
Summary
Chronic intrathecal baclofen infusion effectively treated severe spasticity in 14 patients with central or spinal cord damage. This therapy improved motor function, reduced spasms, and enhanced quality of life with no reported side effects.
Area of Science:
- Neurology
- Neurosurgery
- Rehabilitation Medicine
Background:
- Severe spasticity resulting from central or spinal cord damage poses significant challenges.
- Conservative treatments often fail to provide adequate relief for these debilitating conditions.
Purpose of the Study:
- To evaluate the efficacy and safety of chronic intrathecal baclofen infusion in patients with severe, treatment-resistant spasticity.
Main Methods:
- 14 patients with severe spasticity underwent a percutaneous trial before chronic intrathecal baclofen infusion via programmable pumps.
- Baclofen delivery sites varied based on patient condition (quadriplegic vs. paraplegic).
- Daily doses ranged from 25 to 260 micrograms, administered via bolus, continuous infusion, or a combination.
Main Results:
- A mean follow-up of 11 months showed a consistent decrease in rigidity and absence of spasms.
- Significant improvements were noted in bladder function, remission of cramping pain, and moderate gains in walking capacity and transfers.
- No complications or adverse side effects were reported during the study period.
Conclusions:
- Chronic intrathecal baclofen infusion is a safe and effective treatment for severe spasticity in patients with central or spinal cord damage.
- This therapeutic approach offers substantial improvements in functional outcomes and quality of life.